Dabigatran Polymorphic patent application rejected

Dabigatran is an anticoagulant thrombin inhibitor marketed by Boehringer and marketed as Pradaxa. The Dabigatran’s product patent is granted in india (370/DEL/1998 granted as 225735). It is marketed as dabigatran etexilate mesylate. This mesylate salt form of dabigatran prodrug (etexilate) is protected by WO2003074056 and WO2005028468.

The ‘056 patent application is also granted in India as 231731 (2251/DELNP/2004) and  the ‘468 application equivalent 924/DELNP/2006, is now rejected by IPO which covers polymorphic form of dabigatran etexilate mesylate

Decision is available at IPO site

About Guna

Interested to learn things around me
This entry was posted in Daily interesting IP news. Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s